pipette
ESEspañol

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Ben George, Harshabad Singh, Craig Devoe, Vincent M. Chung, Peter J. Hosein, Andrew Hendifar, Dae Won Kim, Jennifer Brooke Valerin, Tanios Bekaii‐Saab, Dana Backlund Cardin, Manuel M. Hidalgo, Pashtoon Murtaza Kasi, Alexis Diane Leal, Meredith S. Pelster, Naomi H. Fei, Colin D. Weekes, Mark H. O’Hara, Thomas J. George, Syed Mohammad Ali Kazmi, Jonathan D. Mizrahi, Suresh Nair, Martin J. Maiers, Thian San Kheoh, Gianni Amato, Jino Xavier, Julia Priscilla Snyder, Madison H. Milaszewski, Xavier Cabana-Puig, James Perry, Lisa Kristin McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Zev A. Wainberg, Eileen Mary O'Reilly

Peer-reviewed journalReal-world use

In the authors' words

Camupepimut (ELI-002 7P) drives mutated KRAS (mKRAS)-specific T cell responses that correlated with disease-free survival (DFS) and overall survival (OS) in patients with mKRAS pancreatic adenocarcinoma (PDAC) in the phase 1 AMPLIFY-201 trial. In the phase 2 AMPLIFY-7P trial, patients with stage I-III KRAS-mutated PDAC without recurrence within 6 months of standard therapy were randomized 2:1 to camupepimut (n = 96) or standard-of-care/observation (n = 48). Stratification balanced nodal status. The primary DFS endpoint was not met (median 23.8 versus 21.2 months; HR 0.85, P = 0.5329). However, prespecified and exploratory analyses were informative. A numerical DFS advantage at 6 months of 14.0% (75.7% versus 61.7%; HR 0.55, P = 0.0557) corresponded to camupepimut dosing. Post hoc multivariate Cox regression analysis of DFS indicated an improved outcome for camupepimut (adjusted HR 0.47, P = 0.0086), a worse outcome for stage III disease (adjusted HR 2.29, P = 0.0127), an elevated baseline CA19-9 (adjusted HR 3.16, P < 0.0001) and baseline circulating tumor DNA (ctDNA) positivity (adjusted HR 5.99, P < 0.0001). Prespecified subgroup analyses addressing prognostic and predictive factors suggested DFS benefit for camupepimut (ctDNA negative: HR 0.51, P = 0.0280; no prior radiation: HR 0.59, P = 0.0221). Exploratory analysis demonstrated that ex vivo mKRAS-specific T cell responses were robust (98.9%, 89/90) and associated with antigen spreading (86.7%, 13/15). In camupepimut-treated patients, mKRAS-specific T cell response >9.17-fold over baseline (82.2%, 74/90) correlated with improved DFS (HR 0.22, P < 0.0001), with the median DFS not reached versus 6.08 months for above and below 9.17-fold, respectively. Camupepimut safety was similar to observation, with grade ≥3 adverse events in 10.4% (10/96) versus 14.6% (7/48), and few serious AEs (6.3%, 6/96 versus 8.3%, 4/48; reflecting progression/surgical complication). These efficacy and immunogenicity signals will inform a refined strategy for a confirmatory phase 3 trial. ClinicalTrials.gov identifier: NCT05726864 . As presented at the ESMO Congress 2026, in a randomized phase 2 trial evaluating an off-the-shelf lymph node-targeting peptide vaccine in patients with mutated KRAS pancreatic cancer within 6 months of standard curative intent therapy, the primary endpoint of disease-free survival was not met, but prespecified subgroup analyses showed significant disease-free survival benefit in the vaccine arm for patients with circulating tumor DNA-negative disease and in those without prior radiation treatment.

Main resultLimitation the authors admit

Appeared: Sunday, October 25. Nature Medicine. Peer-reviewed journal.

DOI: 10.1038/s41591-026-04734-7